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Abstract
Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection
and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have
reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical
benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several
clinical trials evaluating novel immunotherapy agents—as single agents, combinations and in conjunction with chemother-
apy—in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses vari-
ous immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.
Key words: immunotherapy; colorectal cancer; checkpoint inhibition/blockade; programmed death 1 (PD-1); cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4); vaccine; pembrolizumab
Introduction
Colorectal cancer (CRC) is the third most common cancer in
males and the second most common in females [1]. At the time
of diagnosis, more than 20% of patients have metastatic disease
and the survival rate of CRC patients with distant metastasis is
estimated to be 12% [2–4]. Although, due to significant strides in
surgical management, chemotherapy and biological therapy,
average survival for advanced disease now approaches 30
months, metastatic CRC still remains the fourth most common
cause of death from cancer.
The significance of the immune system in the biology of CRC
is emphasized by retrospective assessments of immune infil-
trates in resected CRC tumors. The presence of tumor infiltrat-
ing lymphocytes—especially CD8þ lymphocytes—in the tumor
microenvironment, as well as regional lymph nodes, has been
linked to better prognosis [5]. Also, increased infiltration of spe-
cific regions of the CRC tumors by cytotoxic memory T lympho-
cytes (CD8þCD45ROþT-cells) is highly correlated with reduced
risk of recurrence of CRC and better survival [6, 7]. It is also
known that the presence of these effector memory T-cells is
more important than naı¨ve T-cells in reducing the risk of re-
lapse and improving survival. The prognostic significance of T-
cells—unlike other inflammatory cells—argues that cancer
immunotherapies modulating T-cell responses could lead to
improved survival.
Recent developments in immune-biotechnology and the dis-
covery of immunotherapy agents—specifically checkpoint in-
hibitors—have been promising for treatment of melanoma [8, 9]
and non–small cell lung cancer [10], leading to regulatory ap-
proval of these novel drugs. The significant activity of these
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agents in various epithelial tumors raises the prospect that the
immune system may represent a favorable avenue for advanc-
ing the management of patients with CRC. This review focuses
on current utilization of checkpoint blockade, as well as other
immunotherapy agents, and their potential integration into ex-
isting therapeutic regimens for advanced colorectal cancers.
Immune checkpoints: biology and
preclinical studies
T-lymphocytes act as the chief effector cells in the immune re-
sponse against tumor cells by recognizing and mounting a cyto-
toxic response against antigenic molecules arising out of the
genetic and epigenetic alterations that mark malignant trans-
formation. The immune response is initiated by the recognition
of antigenic peptides presented by the major histocompatibility
complex (MHC) on the surface of antigen-presenting cells by the
T-cell receptor (TCR). TCR engagement alone is insufficient to
lead to the clonal expansion and differentiation required for an
effective and lasting immune response against the offending
antigen. Additional co-stimulatory signals are required for cyto-
kine production, targeT-cell lysis and effector cell responses
(Figure 1). There also exists an intricate system of inhibitory sig-
nals (immune checkpoints), which is crucial in the maintenance
of peripheral immune-tolerance and preventing auto-
immunity. The amplitude and duration of the T-cell response
depends on the balance between co-stimulatory and inhibitory
signals. T-cell responses may be amplified by agonists of co-
stimulatory receptors or antagonists of inhibitory signals. As
the immune checkpoints are often co-opted by tumors to es-
cape immune surveillance, inhibitors of immune checkpoints
lead to revival of tumor immunity. The two checkpoint targets
that have been studied more extensively in cancer are the cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA-4) and the pro-
grammed death 1 (PD-1) receptor (Figure 1). Other targets, like
lymphocyte activation gene 3 (LAG-3), are also being studied
and early phase clinical trials are under way.
Cytotoxic T-lymphocyte-associated antigen 4
There are several membrane protein ligands on antigen pre-
senting cells (APC), which interact with specific receptors on T-
cells to produce a co-stimulatory signal or a co-inhibitory signal
to enhance or decrease the T-cell immune response. B7 protein
found on activated APC can pair with CD28 on T-cells, leading
to amplification of TCR signaling, or cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) (CD152) surface protein on a
T-cell inhibiting T-cell activation and cytokine production with
induction of a state of anergy and proliferative arrest [11].
Figure 1. Checkpoint blockade in tumor immunotherapy. T-cells initiate the immune response though recognition of antigenic peptides presented by the MHC on the
surface of antigen-presenting cells and cancer cells through their TCR. TCR engagement alone is insufficient to turn on a T-cell response, and additional co-stimulatory
signal via B7 are required for cytokine production, targeT-cell lysis and effector cell responses. B7 protein can pair with CD28 on T-cells, leading to amplification of TCR
signaling, or CTLA-4 on a T-cell inhibiting T-cell activation. PD-1 primarily inhibits effector T-cell activity in the effector phase within tissue and tumors—unlike CTLA-
4, which mainly modulates early steps in T-cell activation. PD-1 inhibitory receptor is expressed by T-cells during long-term antigen exposure and results in inhibition
of T-cells on interaction with PD-L1, which is expressed in the tumor microenvironment. Immune checkpoint blockade via monoclonal antibodies leads to preferential
activation of cancer-specific T-cells and revival of tumor immunity (MHC: major histocompatibility complex; TCR: T-cell receptor; CTLA-4: cytotoxic T-lymphocyte-
associated antigen 4; PD-1: programmed death 1; PD-L1: programmed death-ligand 1).
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The crucial role of CTLA4-B7 interaction in immune homeo-
stasis is demonstrated by the fact that CTLA-4 knockout mice
develop lethal lymphoproloferative disorders [12]. Regulatory T-
lymphocytes (Treg) exhibit the constitutive expression of CTLA-4
and their suppressive function in vivo can be suppressed by
blocking CTLA-4 [13, 14]. Allison et al. reported in 1996 that
blocking CTLA-4 function could not only enhance rejection of
transplanted colon carcinoma in mice, but also delay the
growth of established tumors [15]. In a CT-26 colon carcinoma
model, a combination of an anti-CTLA-4 monoclonal antibody
with ixabepilone or paclitaxel resulted in a 50–70% tumor rejec-
tion rate [16]. An enhanced anti-tumor response at the primary
site—as well as an abscopal effect—was observed when frac-
tionated radiotherapy was combined with an anti-CTLA-4
monoclonal antibody in a murine colon cancer model MCA38
[17]. In another study that utilized the same model, a combina-
tion of anti-CTLA-4 and anti-4-1BB-enhanced CD8 T-cell medi-
ated anti-tumor response and significantly reduced liver
metastasis when compared with treatment utilizing either anti-
body alone [18].
Programmed death 1
Programmed death 1 (PD-1) primarily inhibits effector T-cell ac-
tivity in the effector phase within tissue and tumors—unlike
CTLA-4, which mainly modulates early steps in T-cell activation
[19]. PD-1 binds to two distinct members of the B7 family: pro-
grammed-death ligands 1 and 2 (PD-L1 and PD-L2). PD-L1 has a
very broad expression range, which includes hematopoietic
cells such as dendritic cells (DC), macrophages, T-cells and B
cells, as well as non-hematopoietic cells such as epithelial and
endothelial cells [20, 21]. PD-L2 has a more restricted expression
profile limited to macrophages, DC and masT-cells. PD-1-
deficient mice develop a delayed-onset, organ-specific auto-
immunity, which is in contrast with the rapid-onset systemic
autoimmunity that characterizes CTLA-4-deficient mice [22].
When BALB/c mice bearing CT-26 colon tumors were treated
with anti-PD-1 antibodies as single-agents, there was growth re-
tardation but no eradication of tumors, which notably could be
accomplished with dual blockade of PD-1 and CTLA-4 [23]. Iwai
et al. intravenously injected PD-1 knockout mice (PD-1-/-) and
wild-type (WT) mice with CT26 colon cancer cells to mimic met-
astatic spread, and found that tumor formation in the lungs
was significantly reduced in the PD-1-/- mice. Treatment with
anti-PD-1 antibodies also had the same effect [24]. The addition
of anti-PD-L1 antibodies was reported to potentiate the survival
benefit imparted by IL-15 in a metastatic colorectal cancer mu-
rine model. The greatest survival benefit in this study was
observed when IL-15 was combined with anti-PD-L1 and anti-
CTLA-4 treatment [25]; in a syngeneic murine colon cancer
model, anti-PD-L1, when combined with ionizing radiation, ef-
fectively controlled tumor growth, which could not be achieved
with either treatment alone, indicating synergy or an abscopal
effect with radiation therapy [26].
While single or dual checkpoint blockade causes significant
improvements in anti-tumor immune response, there is poten-
tial to further boost this response with additional immune-
sensitizing strategies. In one study, treatment with anti-PD-1 or
anti-PD-L1 or anti-CTLA4 alone caused CT-26 colon tumors to
be rejected in 25%, 33%, and 50% of the mice injected, respec-
tively, which increased to 75% with dual blockade. Remarkably,
a complete (100%) tumor rejection was observed when dual
blockade was combined with a cancer vaccine, GVAX [27].
Lymphocyte activation gene 3
Lymphocyte activation gene 3 (LAG-3) is another molecule ex-
pressed on activated T-cells, with diverse biological effects on
T-cell function. Its main ligand is MHC class II, and LAG-3/MHC
class II interaction down-regulates antigen-dependent stimula-
tion of CD4þ T lymphocytes [28]. The protein negatively regu-
lates the cellular proliferation, activation, and homeostasis of
T-cells in a similar fashion to CTLA-4 and PD-1, and has been re-
ported to play a role in the Treg suppressive function [29–31].
LAG-3 also helps to maintain CD8þ T-cells in a tolerogenic state
[32] and, working with PD-1, helps to maintain CD8 exhaustion
during chronic viral infection [33].
Immunotherapy for colorectal cancer
Non-specific immunotherapy and immunomodulatory
effects of chemotherapy
Cytokines such as interferon (IFN), interleukins and granulocyte
macrophage colony-stimulating factor (GM-CSF) constitute
non-specific immunotherapy, which augments host immunity
against tumor antigens. Conventional chemotherapies also
may have some effect through the immune system. Oxaliplatin
triggers a form of cell death that is thought to be immunogenic,
whereas the chemical analogue cisplatin does not trigger the
same form of immunogenic cell death. In preclinical models, in-
jection with oxaliplatin-killed CRC cells enhances the survival
of mice that are subsequently challenged with live CRC cells
and this protection requires an intact immune system [34]; thus
the anti-tumor activity of oxaliplatin may also be related to its
efficacy as an immune-modulatory agent and not solely as a cy-
totoxic drug.
A Phase II trial of gemcitabine, oxaliplatin and 5-fluorouracil
(GOLF), combined with IL-2 and GM-CSF immune-adjuvant regi-
men (GOLFIG) in patients with CRC showed an overall response
rate (ORR) of 56.5% and mean overall survival (OS) of nearly 19
months. Autoimmunity and substantial increase in lymphocyte
count were found to be predictors for OS [35]. The GOLFIG-2
chemo-immunotherapy trial was a Phase II I multicenter
study comparing GOLFIG with 5-fluorouracil/leucovorin plus
oxaliplatin (FOLFOX) in chemotherapy-naı¨ve, metastatic CRC
patients. The study suffered early termination because of poor
recruitment in the control arm, but GOLFIG showed superiority
over FOLFOX in terms of progression free survival (PFS) and
ORR, with a trend towards improvement of OS [36]. These find-
ings provide proof-of-principle that chemo-immunotherapy
may represent a novel option for first-line treatment of meta-
static CRC.
Immune checkpoint inhibitors
The development of checkpoint inhibitors is largely responsible
for the recent excitement about immunotherapy. These agents
are blocking antibodies to inhibitory cell-surface molecules,
such as CTLA4 and PD-1/PD-L1, which restrain the priming and
effector phases, respectively, of the adaptive T-cell immune re-
sponse. The PD-1 pathway is a negative feedback system that
represses Th1 cytotoxic immune responses. It is up-regulated in
many tumors and, in their surrounding microenvironment and
its blockade with antibodies to PD-1 or its ligands, has led to re-
markable clinical responses in patients with various types of
cancer [10, 37–39]. The expression of PD-1 ligands (PD-L1 or PD-
L2) on the surface of tumor cells or immune cells is an
important—but not a definitive—predictive biomarker of
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response to PD-1 blockade [38–41]. The clinical activity of check-
point inhibitors in CRC needs to be evaluated in larger numbers
of patients, in trials that examine predictive biomarkers, as well
as combine these agents with conventional therapies. Table 1
summarizes the results of checkpoint inhibitor clinical trials in
patients with CRC.
Anti-PD-1/PD-L1
The anti–PD-1 antibody nivolumab did not demonstrate clini-
cally significant activity in a Phase I study of multiple tumor
types, which included 17 patients with heavily pre-treated, met-
astatic CRC. However, six of the seven tumors found in this co-
hort, which were tested for PD-L1 expression, were negative,
potentially explaining the observed lack of response [37].
Notably, one patient from this metastatic-CRC cohort, who had
a PD-L1 positive tumor and was treated with 5 doses of nivolu-
mab, showed complete response after 6 months and no signs of
disease after 3 years. This patient’s tumor was also mismatch-
repair-deficient [42].
Pembrolizumab is a humanized IgG4 monoclonal antibody
that blocks the interaction of PD-1 with its ligands PD-L1 and
PD-L2. A Phase II trial of pembrolizumab evaluated 32 patients
with advanced CRC [11 with deficient mismatch repair (dMMR)
and 21 with proficient mismatch repair (pMMR)] [43]. All pa-
tients enrolled in the study had received two or more (median
of four) previous chemotherapy regimens, except one patient
who had received one chemotherapy regimen and one non-PD-
1 based immunotherapy before. The immune-related objective
response rate and patients with stable disease were signifi-
cantly higher in the dMMR CRC patients (40% and 78%, respec-
tively) than in the pMMR CRC patients (0% and 11%,
respectively). Similar findings were observed in the cohort with
dMMR cancers other than CRC. Based on this a larger, Phase II
study (Keynote-164) is currently enrolling patients to assess the
benefit of pembrolizumab for unresectable or metastatic dMMR
CRC refractory to two or more previous lines of therapy
(NCT02460198).
The anti–PD-L1 antibody BMS936559 showed no activity in a
Phase I trial that included 18 patients with CRC [44]. However,
preliminary data with another anti–PD-L1 antibody MPDL3280A
showed activity in CRC with one of four patients achieving a du-
rable partial response [45]. Another Phase Ib trial, assessing
MPDL3280A in combination with bevacizumab in refractory CRC
patients and in combination with FOLFOX plus bevacizumab in
first-line CRC, showed good tolerability and clinical activity
[unconfirmed ORR 8% (1/13) and 44% (8/18), respectively] [46].
Mismatch repair deficiency and checkpoint inhibition
A dMMR system is present in 10–20% of patients with sporadic
CRC and is associated with a favorable prognosis in early-stage
disease. In contrast, dMMR occurs in only 3–6% of patients with
advanced CRC [47, 48]. As the immune system can recognize so-
matic mutations found in tumors [49]—and as colorectal tumors
with dMMR have several times as many somatic mutations as
proficient MMR tumors [50, 51]—it has been hypothesized that
the immune system may play a role in dMMR tumors possess-
ing a reduced metastatic potential. Additionally, dMMR cancers
have prominent lymphocyte infiltrates [52, 53], which supports
the above hypothesis. Furthermore, recent findings have sug-
gested that the infiltrate in dMMR CRC is more likely to express
PD-L1, which may predict response to PD-1 blockade [54]. Thus
checkpoint inhibitors may have increased activity in dMMR
tumors, a hypothesis which was tested in a Phase II trial. This
study showed that MMR status may be a predictive biomarker
for clinical benefit from checkpoint inhibition [43]. Although im-
munotherapy in dMMR tumors holds great promise, the com-
plete absence of response in patients with pMMR CRC—who
represent the vast majority—highlights the ongoing need to un-
derstand why patients with conventional CRC lack robust re-
sponses to immunotherapy.
CTLA-4
Tremelimumab is a fully human IgG2 monoclonal antibody that
blocks the inhibitory action of CTLA-4, and was tested as a
monotherapy in a single-arm, Phase II trial in 47 patients with
refractory metastatic CRC [55]. All the patients were heavily pre-
treated and most had also received cetuximab. Tremelimumab
did not show significant single-agent activity in this study,
which could be due to delayed immune responses in the setting
of advanced CRC, since 43 of 45 patients experienced disease
progression with a median duration on study of only 2.3
months. The first FDA-approved CTLA-4 monoclonal antibody,
ipilimumab, is currently being evaluated in combination with
nivolumab (anti-PD-1 antibody) in clinical trials for metastatic
CRC patients with dMMR tumors (NCT02060188).
Other immune checkpoint inhibitors
Tumors with mismatch repair deficiency also have a high
expression of immune checkpoint ligands such as PD-L1, PD-1,
CTLA-4, and LAG-3, which effectively counterbalance the active
Th1 response and prevent tumor elimination. These immune
checkpoints function as possible targets for inhibition during
cancer immunotherapy [56]. Anti-LAG-3 monoclonal antibodies
(BMS-986016), alone and in combination with nivolumab, are
already undergoing evaluation in clinical trials (NCT01968109).
These are promising future targets for immune checkpoint
inhibition.
Vaccine-based immunotherapy
Whole-tumor-cell vaccines
The earliest attempts to generate anti-CRC immune responses
were in the form of whole-tumor-cell vaccines. Most studies
have used autologous CRC tumor cells in combination with
Bacillus Calmette-Gue´rin (BCG). The Eastern Cooperative
Oncology Group (ECOG) E5283 was a randomized, Phase II I trial
that randomly assigned 412 patients with resected stage II and
III colon cancer to an observation arm or a treatment arm with
autologous tumor-cell-BCG vaccine. After a median follow-up of
7.6 years, no statistically significant differences were seen in
terms of clinical outcomes but effective immune responses—
observed as delayed cutaneous hypersensitivity (measured as
skin induration)—correlated positively with disease-free sur-
vival (DFS) and OS [57]. Another trial assessed the efficacy of
three post-operative vaccinations, followed by a booster dose 6
months later, in 254 resected stage II and III CRC patients. The
study showed a 44% reduction in risk of recurrence in the vac-
cine group [58]. This study showed the importance of vaccine
quality control for proper immunogenicity, as 12% of vaccines
in the ECOG trial failed to meet quality control specifications.
Delayed cutaneous hypersensitivity was also shown to be an ef-
fective surrogate endpoint in monitoring the long-term efficacy
of tumor cell vaccines [59]. A meta-analysis of all trials evaluat-
ing this strategy in resected stage II and stage III CRC reported a
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significant improvement in OS (HR¼ 0.76; P¼ 0.007) and DFS
(HR¼ 0.76; P¼ 0.03) [59].
As observed in early trials, autologous whole-tumor-cell vac-
cines were poorly immunogenic, which was probably due to
paucity of tumor-associated antigens (TAAs) in whole-cell vac-
cines and the large proportion of antigens shared with normal
cells [60]. Another tumor-cell vaccine approach, utilizing
Newcastle disease virus-infected, irradiated, autologous tumor
cells (ATV-NDV) was tested in a Phase II trial. Of patients treated
with ATV-NDV, 61% developed tumor recurrence, compared
with 87% treated with surgery alone [61]; however, in terms of
overall survival, a Phase II I trial with 50 patients failed to show
significant improvement for ATV-NDV-treated patients, al-
though a sub-group analysis showed benefit for colon—but not
rectal—cancer patients [62].
GVAX, a GM-CSF gene-transfected tumor-cell vaccine, has
shown immune-stimulatory action in several cancers [63].
There is a current pilot study using GVAX in irradiated autolo-
gous CRC cells in patients with stage IV CRC, which examines
safety as a primary endpoint, as well as progression-free sur-
vival (PFS) and OS (NCT01952730).
Peptide vaccines
Peptide vaccines incorporate one or more short or long amino
acid sequences as tumor antigens, combined with a vaccine ad-
juvant. Several TAAs expressed by colorectal cancer cells—such
as carcino-embryonic antigen (CEA), MUC-1, survivin, beta-hu-
man chorionic gonadotropin (hCG) and ring finger protein 43
(RNF43)—have been targeted via peptide vaccines. Results have
been modest, with only a few patients showing clinical re-
sponse, despite demonstration of antigen-specific T-cell re-
sponses following vaccination.
A Phase I safety study, using plasmid DNA vaccine-encoding
CEA (CEA66 DNA) alongside GM-CSF in CRC patients, showed
good tolerability with no signs of autoimmunity [64]. In another
Phase I trial, HLA-A24-specific survivin-2B vaccine was adminis-
tered to 15 patients with advanced or recurrent CRC expressing
survivin, with one patient showing an increase in survivin-spe-
cific CTLs and six showing decreased CEA levels [65]. A cohort of
21 CRC patients, treated with a peptide-cocktail vaccine derived
from RNF43 and translocase of the outer mitochondrial mem-
brane 34 (TOMM34), showed antigen-specific CTL responses to
both RNF43 and TOMM34 in 8/21 and CTL response to only one
of the peptides in 12 out of 21 patients. Interestingly, survival
rates were lowest in the patients who showed no CTL responses
[66]. Another TAA of interest is hCG, which is not produced by
normal colorectal epithelial and mucosal cells or benign lesions.
Moulton et al. studied the effect of hCG peptide vaccination in
77 patients with stage IV CRC, most of whom had a history of
chemotherapy with one or more agents; anti-hCG antibodies
were observed in 56 out of 77 patients and a longer survival was
seen in patients with higher-than-median levels of antibody
[67].
Viral vector vaccines
The immunogenicity of peptide vaccines is low, and could be
amplified by packaging the peptide in a viral or bacterial vector.
Several groups have attempted to use immunogenic viral vec-
tors expressing CRC TAAs to stimulate anti-CRC immune re-
sponses. A Phase I study with ALVAC-CEA, a canary pox virus
expressing CEA and B7.1 co-stimulation, exhibited an accept-
able safety profile in 118 patients. Objective responses were
seen in 42 (40%) patients, whereas another 42 (40%) had stable
disease, with several patients demonstrating CEA-specific T-cell
responses [68]. Similar results were seen with a recombinant
fowl pox virus expressing multiple co-stimulatory molecules
(B7.1, LFA-3, ICAM-1) and the CEA antigen—administered alone
or in sequence with a recombinant vaccinia virus expressing
the same molecules—to patients with a variety of CEA-
expressing tumors, including 35 patients with CRC. Most pa-
tients showed an increase in CEA-specific T-cells, and durable
disease stability of at least 4 months was observed in 40% of pa-
tients (23 out of 58).
Dendritic cell vaccines
Dendritic cells (DCs) are crucial for cell surface presentation of
endogenous and exogenous immunogenic peptides and activa-
tion of T-cells. Various strategies for delivering TAAs to DCs
through synthetic peptides [69], tumor RNA [70], and tumor cell
lysates [71] have been developed to stimulate an adequate CTL
response. Phase I clinical studies using autologous human DCs,
pulsed with CEA peptide, in CEA-expressing metastatic CRC pa-
tients showed the vaccine to be safe and well tolerated,
although only a modest clinical improvement was observed
[72]. Another Phase I study used CEA-derived peptide loaded
onto DCs, plus a vaccine adjuvant (Flt3-ligand). After vaccina-
tion, 2 of 12 patients experienced dramatic tumor regression,
one patient had a mixed response, and two exhibited stable dis-
ease [73]. Antigen selection remains a key issue with these den-
dritic cell–based vaccination approaches, and overall success
rates have been modest.
Adoptive cell transfer therapy
Adoptive cell transfer therapy (ACT) is a technique in which au-
tologous T-cells are extracted from patients, activated, ex-
panded in vitro and re-injected into patients. Adoptive cell
therapies have shown some activity in CRC, using autologous T-
cells genetically engineered to express high-affinity receptors
for CRC TAAs. ACT enables the selection and activation of
highly reactive T-cells, with clinical responses observed even in
advanced CRC [74]. In a Phase I study, autologous T-cells, genet-
ically engineered to express a high-affinity murine T-cell recep-
tor against human CEA, were administered to three patients
with refractory CRC. Serum CEA levels decreased significantly
(74–99% reduction) in all patients and one patient exhibited an
objective decrease in tumor size. But further enrollment of
patients was halted because all three patients developed auto-
immune colitis (two patients with grade 3) [75]. This was the
first study in which an objective regression was noted in meta-
static colorectal cancer through ACT. Morgan et al. used HER2-
specific chimeric antigen receptor (CAR) T-cells for patients
with metastatic CRC, but failed to demonstrate its safety and ef-
ficacy due to severe side-effects [76]. Further studies on this
front could possibly lead to safe and efficacious ACT therapy for
CRC. Various trials are in progress in this field of investigation,
including a Phase I dose escalation of infusion of CTLs specific
for TAAs NY-ESO-1, MA-GEA4, PRAME, Survivin, and SSX in re-
lapsed or refractory solid tumors (NCT02239861), and a Phase I/
II study of the safety and efficacy of infusion of peripheral blood
lymphocytes transduced with a CAR that is specific for VEGF-2
in metastatic CRC following a lympho-depleting conditioning
regimen with cyclophosphamide and fludarabine
(NCT01218867).
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Special considerations with immunotherapy
The kinetics of clinical responses with immunotherapy can be
very dissimilar to conventional therapies such as chemother-
apy. A shared feature of several of the approved immune thera-
pies (in particular cytokines and checkpoint inhibitors) is that
only a small fraction of patients have early objective response
using standard RECIST criteria. It is not uncommon for some le-
sions to grow prior to regression, and patients may often dem-
onstrate a lag in apparent clinical response. Specific immune-
related response criteria have been developed to overcome this
shortcoming. These criteria allow for some interval progression,
as long as the patient is not deteriorating significantly [77].
These criteria should be routinely incorporated into immuno-
therapy clinical trials for CRC.
Another crucial question is the most appropriate clinical set-
ting in which to study immunotherapy in CRC. Although the
time lag in clinical response may suggest using these earlier in
the course of metastatic CRC—or possibly even in neoadjuvant
or adjuvant setting—currently approved indications for immu-
notherapies in melanoma and non-small cell lung cancer are
for advanced disease often pre-treated with chemotherapy.
Most of the current investigations are being carried out in ad-
vanced CRC; a few trials combining checkpoint inhibition with
up-front FOLFOX chemotherapy are being evaluated for first-
line treatment of metastatic CRC (NCT02375672).
Immunotherapies are also associated with some peculiar
auto-immune adverse events, such as colitis, hepatitis, and
endocrinopathies for checkpoint inhibitors such as ipilimumab
and nivolumab [8, 37]. These toxicities appear to be less pro-
nounced with the PD-1/PD-L1 inhibitors, although pneumonitis
has been reported with these agents. Toxicities with PD-1/PD-L1
are generally manageable with corticosteroids and tumor necro-
sis factor (TNF)-a inhibitors.
Future directions
The approval of more drugs in this novel class of immune
checkpoint inhibitors—as well as development of several newer
immunotherapies that are undergoing testing in clinical trials—
would continue to provide innovative insights relevant to future
investigations of CRC immunotherapy. Although PD-L1 expres-
sion and dMMR tumors are currently showing promise as pre-
dictive biomarkers for response to checkpoint inhibitors, it is
necessary to identify specific patient sub-groups, in the appro-
priate clinical setting, that would benefit most from
immunotherapy.
It is also imperative to study rational combinations involving
immunotherapy drugs. Given the evidence for immunogenic
cell death triggered by oxaliplatin, the combination of first-line
FOLFOX chemotherapy and checkpoint inhibition holds signifi-
cant promise. As checkpoint inhibitors are thought to enhance
pre-existing immune response to tumor antigens by releasing
tumor-induced inhibition of the immune response, combina-
tions of antigen-directed therapies (e.g. vaccines), sequentially
followed by checkpoint inhibition, may also be a rational ap-
proach in CRC.
Another novel strategy being currently evaluated involves
stimulation of anti-tumor immune response using urelumab
that activates co-stimulatory CD137 receptor. Combining this
approach with checkpoint inhibition (activate co-stimulatory
receptors and inhibit co-inhibitory receptors) appears promising
and a Phase I trial of urelumab in combination with nivolumab
is currently enrolling subjects (NCT02534506). Another clinical
trial of urelumab in combination with cetuximab is also under-
way in metastatic CRC patients (NCT02110082).
Conclusion
Current clinical trials of immunotherapy in CRC—specifically
checkpoint inhibitors—are already suggesting its efficacy in
carefully selected subsets of patients with CRC. Developing reli-
able, predictive biomarkers and understanding the mechanisms
that underlie lack of response or resistance to these agents re-
mains a challenge. Based on their demonstrated effectiveness
in a broad range of solid malignancies, immunotherapies hold
great promise in CRC.
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References
1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012.
CA Cancer J Clin 2015;65:87–108.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA
Cancer J Clin 2013;63:11–30.
3. Kerr D. Clinical development of gene therapy for colorectal
cancer. Nat Rev Cancer 2003;3:615–22.
4. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer.
Lancet 2010;375:1030–47.
5. Oberg A, Samii S, Stenling R et al. Different occurrence of
CD8þ, CD45R0þ, and CD68þ immune cells in regional lymph
node metastases from colorectal cancer as potential prognos-
tic predictors. Int J Colorectal Dis 2002;17:25–29.
6. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and lo-
cation of immune cells within human colorectal tumors pre-
dict clinical outcome. Science 2006;313:1960–4.
7. Pages F, Kirilovsky A, Mlecnik B et al. In situ cytotoxic and
memory T-cells predict outcome in patients with early-stage
colorectal cancer. J Clin Oncol 2009;27:5944–51.
8. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J
Med 2010;363:711–23.
9. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus in-
vestigator-choice chemotherapy for ipilimumab-refractory
melanoma (KEYNOTE-002): a randomised, controlled, phase
2 trial. Lancet Oncol 2015;16:908–18.
10.Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus
Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung
Cancer. N Engl J Med 2015;373:123–35.
11.Greenwald RJ, Boussiotis VA, Lorsbach RB et al. CTLA-4 regu-
lates induction of anergy in vivo. Immunity 2001;14:145–55.
12.Waterhouse P, Penninger JM, Timms E et al.
Lymphoproliferative disorders with early lethality in mice
deficient in Ctla-4. Science 1995;270:985–8.
13.Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-
tolerance maintained by CD25(þ)CD4(þ) regulatory T-cells
constitutively expressing cytotoxic T lymphocyte-associated
antigen 4. J Exp Med 2000;192:303–10.
14.Read S, Greenwald R, Izcue A et al. Blockade of CTLA-4 on
CD4þCD25þregulatory T-cells abrogates their function
in vivo. J Immunol 2006;177:4376–83.
15.Leach DR, Krummel MF, Allison JP. Enhancement of anti-tumor
immunity by CTLA-4 blockade. Science 1996;271:1734–6.
16. Jure-Kunkel M, Masters G, Girit E et al. Synergy between
chemotherapeutic agents and CTLA-4 blockade in preclini-
cal tumor models. Cancer Immunol Immunother 2013;62:
1533–45.
Immune checkpoints and immunotherapy for colorectal cancer | 7
 at W
ashington U
niversity, Law
 School Library on N
ovem
ber 3, 2015
http://gastro.oxfordjournals.org/
D
ow
nloaded from
 
17.Dewan MZ, Galloway AE, Kawashima n et al. Fractionated but
not single-dose radiotherapy induces an immune-mediated
abscopal effect when combined with anti-CTLA-4 antibody.
Clin Cancer Res 2009;15:5379–88.
18.Kocak E, Lute K, Chang X et al. Combination therapy with
anti-CTL antigen-4 and anti-4-1BB antibodies enhances can-
cer immunity and reduces autoimmunity. Cancer Res
2006;66:7276–84.
19.Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-
H1 promotes T-cell apoptosis: a potential mechanism of im-
mune evasion. Nat Med 2002;8:793–800.
20.Yamazaki T, Akiba H, Iwai H et al. Expression of programmed
death 1 ligands by murine T-cells and APC. J Immunol
2002;169:5538–45.
21.Eppihimer MJ, Gunn J, Freeman GJ et al. Expression and regu-
lation of the PD-L1 immunoinhibitory molecule on microvas-
cular endothelial cells. Microcirculation 2002;9:133–45.
22.Nishimura H, Nose M, Hiai H et al. Development of lupus-like
autoimmune diseases by disruption of the PD-1 gene encod-
ing an ITIM motif-carrying immunoreceptor. Immunity
1999;11:141–51.
23.Kim K, Skora AD, Li Z et al. Eradication of metastatic mouse
cancers resistant to immune checkpoint blockade by sup-
pression of myeloid-derived cells. Proc Natl Acad Sci USA
2014;111:11774–9.
24. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematog-
enous spread of poorly immunogenic tumor cells by en-
hanced recruitment of effector T-cells. Int Immunol
2005;17:133–44.
25.Yu P, Steel JC, Zhang M et al. Simultaneous blockade of multi-
ple immune system inhibitory checkpoints enhances
anti-tumor activity mediated by interleukin-15 in a murine
metastatic colon carcinoma model. Clin Cancer Res
2010;16:6019–28.
26.Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1
treatment synergistically promote anti-tumor immunity in
mice. J Clin Invest 2014;124:687–95.
27.Duraiswamy J, Kaluza KM, Freeman GJ et al. Dual blockade of
PD-1 and CTLA-4 combined with tumor vaccine effectively re-
stores T-cell rejection function in tumors. Cancer Res
2013;73:3591–603.
28.Huard B, Tournier M, Hercend T et al. Lymphocyte-activation
gene 3/major histocompatibility complex class II interaction
modulates the antigenic response of CD4þ T lymphocytes.
Eur J Immunol 1994;24:3216–21.
29.Huang CT, Workman CJ, Flies D et al. Role of LAG-3 in regula-
tory T-cells. Immunity 2004;21:503–13.
30.Workman CJ, Cauley LS, Kim IJ et al. Lymphocyte activation
gene-3 (CD223) regulates the size of the expanding T-cell pop-
ulation following antigen activation in vivo. J Immunol
2004;172:5450–5.
31.Workman CJ and Vignali DA. The CD4-related molecule, LAG-
3 (CD223), regulates the expansion of activated T-cells. Eur J
Immunol 2003;33:970–9.
32.Grosso JF, Kelleher CC, Harris TJ et al. LAG-3 regulates CD8þ
T-cell accumulation and effector function in murine self- and
tumor-tolerance systems. J Clin Invest 2007;117:3383–92.
33.Blackburn SD, Shin H, Haining WN et al. Coregulation of CD8þ
T-cell exhaustion by multiple inhibitory receptors during
chronic viral infection. Nat Immunol 2009;10:29–37.
34.Tesniere A, Schlemmer F, Boige V et al. Immunogenic death
of colon cancer cells treated with oxaliplatin. Oncogene
2010;29:482–91.
35.Correale P, Tagliaferri P, Fioravanti A et al. Immunity feedback
and clinical outcome in colon cancer patients undergoing
chemoimmunotherapy with gemcitabineþ FOLFOX followed
by subcutaneous granulocyte macrophage colony-
stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin
Cancer Res 2008;14:4192–9.
36.Correale P, Botta C, Rotundo MS et al. Gemcitabine, oxalipla-
tin, levofolinate, 5-fluorouracil, granulocyte-macrophage
colony-stimulating factor, and interleukin-2 (GOLFIG) versus
FOLFOX chemotherapy in metastatic colorectal cancer pa-
tients: the GOLFIG-2 multicentric open-label randomized
phase II I trial. J Immunother 2014;37:26–35.
37.Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and im-
mune correlates of anti-PD-1 antibody in cancer. N Engl J Med
2012;366:2443–54.
38.Topalian SL, Sznol M, McDermott DF et al. Survival, durable
tumor remission, and long-term safety in patients with ad-
vanced melanoma receiving nivolumab. J Clin Oncol
2014;32:1020–30.
39.Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with
nivolumab in relapsed or refractory Hodgkin’s lymphoma. N
Engl J Med 2015;372:311–19.
40.Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of
response to the anti-PD-L1 antibody MPDL3280A in cancer
patients. Nature 2014;515:563–7.
41.Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1
ligands, and other features of the tumor immune microenvi-
ronment with response to anti-PD-1 therapy. Clin Cancer Res
2014;20:5064–74.
42.Lipson EJ, Sharfman WH, Drake CG et al. Durable cancer re-
gression off-treatment and effective reinduction therapy
with an anti-PD-1 antibody. Clin Cancer Res 2013;19:462–8.
43.Le, DT Uram, JN Wang, H et al. PD-1 Blockade in Tumors with
Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509–20.
44.Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of
anti-PD-L1 antibody in patients with advanced cancer. N Engl
J Med 2012;366:2455–65.
45.Herbst RS, Gordon MS, Fine GD et al. A study of MPDL3280A,
an engineered PD-L1 antibody in patients with locally ad-
vanced or metastatic tumors. In ASCO Annual Meeting
Proceedings. 2013;3000.
46.Bendell JC, Powderly JD, Lieu CH et al. Safety and efficacy of
MPDL3280A (anti-PDL1) in combination with bevacizumab
(bev) and/or FOLFOX in patients (pts) with metastatic colorec-
tal cancer (mCRC). In ASCO Annual Meeting Proceedings.
2015;704.
47.Goldstein J, Tran B, Ensor J et al. Multicenter retrospective
analysis of metastatic colorectal cancer (CRC) with high-level
microsatellite instability (MSI-H). Ann Oncol 2014;25:1032–8.
48.Koopman M, Kortman GA, Mekenkamp L et al. Deficient mis-
match repair system in patients with sporadic advanced co-
lorectal cancer. Br J Cancer 2009;100:266–73.
49.Segal NH, Parsons DW, Peggs KS et al. Epitope landscape in
breast and colorectal cancer. Cancer Res 2008;68:889–92.
50.Cancer Genome Atlas N. Comprehensive molecular charac-
terization of human colon and rectal cancer. Nature
2012;487:330–7.
51.Timmermann B, Kerick M, Roehr C et al. Somatic mutation
profiles of MSI and MSS colorectal cancer identified by whole
exome next generation sequencing and bioinformatics anal-
ysis. PLoS One 2010;5:e15661.
52.Dolcetti R, Viel A, Doglioni C et al. High prevalence of acti-
vated intraepithelial cytotoxic T lymphocytes and increased
8 | Preet Paul Singh et al.
 at W
ashington U
niversity, Law
 School Library on N
ovem
ber 3, 2015
http://gastro.oxfordjournals.org/
D
ow
nloaded from
 
neoplastic cell apoptosis in colorectal carcinomas with mi-
crosatellite instability. Am J Pathol 1999;154:1805–13.
53.Smyrk TC, Watson P, Kaul K et al. Tumor-infiltrating lympho-
cytes are a marker for microsatellite instability in colorectal
carcinoma. Cancer 2001;91:2417–22.
54.Zoran G, Snyder C, Yeatts K et al. Programmed death 1 (PD-1)
lymphocytes and ligand (PD-L1) in colorectal cancer and their
relationship to microsatellite instability status. J Clin Oncol
2014;32:5s.
55.Chung KY, Gore I, Fong L et al. Phase II study of the anti-
cytotoxic T-lymphocyte-associated antigen 4 monoclonal an-
tibody, tremelimumab, in patients with refractory metastatic
colorectal cancer. J Clin Oncol 2010;28:3485–90.
56.Llosa NJ, Cruise M, Tam A et al. The vigorous immune micro-
environment of microsatellite instable colon cancer is bal-
anced by multiple counter-inhibitory checkpoints. Cancer
Discov 2015;5:43–51.
57.Harris JE, Ryan L, Hoover HC, Jr.et al. Adjuvant active specific
immunotherapy for stage II and III colon cancer with an au-
tologous tumor cell vaccine: Eastern Cooperative Oncology
Group Study E5283. J Clin Oncol 2000;18:148–57.
58.Vermorken JB, Claessen AM, van Tinteren H et al. Active spe-
cific immunotherapy for stage II and stage III human colon
cancer: a randomised trial. Lancet 1999;353:345–50.
59.Hanna MG, Jr., Hoover HC, Jr., Vermorken JB et al. Adjuvant ac-
tive specific immunotherapy of stage II and stage III colon
cancer with an autologous tumor cell vaccine: first random-
ized phase II I trials show promise. Vaccine 2001;19:2576–82.
60.Lokhov PG and Balashova EE. Cellular cancer vaccines: an up-
date on the development of vaccines generated from cell sur-
face antigens. J Cancer 2010;1:230–41.
61.Schlag P, Manasterski M, Gerneth T et al. Active specific im-
munotherapy with Newcastle-disease-virus-modified au-
tologous tumor cells following resection of liver
metastases in colorectal cancer. First evaluation of clinical
response of a phase II -trial. Cancer Immunol Immunother
1992;35:325–30.
62.Schulze T, Kemmner W, Weitz J et al. Efficiency of adjuvant
active specific immunization with Newcastle disease virus
modified tumor cells in colorectal cancer patients following
resection of liver metastases: results of a prospective ran-
domized trial. Cancer Immunol Immunother 2009;58:61–9.
63.Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vac-
cine. Expert Rev Vaccines 2005;4:259–74.
64.Staff C, Mozaffari F, Haller BK et al. A Phase I safety study
of plasmid DNA immunization targeting carcinoembryonic
antigen in colorectal cancer patients. Vaccine 2011;29:6817–22.
65.Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of
anti-apoptosis protein, survivin-derived peptide vaccine
therapy for patients with advanced or recurrent colorectal
cancer. J Transl Med 2004;2:19.
66.Okuno K, Sugiura F, Hida JI et al. Phase I clinical trial of a novel
peptide vaccine in combination with UFT/LV for metastatic
colorectal cancer. Exp Ther Med 2011;2:73–9.
67.Moulton HM, Yoshihara PH, Mason DH et al. Active specific
immunotherapy with a beta-human chorionic gonadotropin
peptide vaccine in patients with metastatic colorectal cancer:
antibody response is associated with improved survival. Clin
Cancer Res 2002;8:2044–51.
68.Kaufman HL, Lenz HJ, Marshall J et al. Combination
chemotherapy and ALVAC-CEA/B7.1 vaccine in patients
with metastatic colorectal cancer. Clin Cancer Res 2008;14:
4843–9.
69.Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed
dendritic cells induce antigen-specific CTL-mediated protec-
tive tumor immunity. J Exp Med 1996;183:283–7.
70.Koido S, Kashiwaba M, Chen D et al. Induction of anti-tumor
immunity by vaccination of dendritic cells transfected with
MUC1 RNA. J Immunol 2000;165:5713–19.
71.Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma
patients with peptide- or tumor lysate-pulsed dendritic cells.
Nat Med 1998;4:328–32.
72.Morse MA, Deng Y, Coleman D et al. A Phase I study of
active immunotherapy with carcinoembryonic antigen
peptide (CAP-1)-pulsed, autologous human cultured dendritic
cells in patients with metastatic malignancies expressing car-
cinoembryonic antigen. Clin Cancer Res 1999;5:1331–8.
73.Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccina-
tion with Flt3 ligand expanded dendritic cells for tumor im-
munotherapy. Proc Natl Acad Sci U S A 2001;98:8809–14.
74.Soda H, Koda K, Yasutomi J et al. Adoptive immunotherapy
for advanced cancer patients using in vitro activated cyto-
toxic T lymphocytes. J Surg Oncol 1999;72:211–17.
75.Parkhurst MR, Yang JC, Langan RC et al. T-cells targeting carci-
noembryonic antigen can mediate regression of metastatic
colorectal cancer but induce severe transient colitis. Mol Ther
2011;19:620–6.
76.Morgan RA, Yang JC, Kitano M et al. Case report of a serious
adverse event following the administration of T-cells trans-
duced with a chimeric antigen receptor recognizing ERBB2.
Mol Ther 2010;18:843–51.
77.Hoos A, Eggermont AM, Janetzki S et al. Improved Endpoints
for Cancer Immunotherapy Trials. J Nat Cancer Inst
2010;102:1388–97.
Immune checkpoints and immunotherapy for colorectal cancer | 9
 at W
ashington U
niversity, Law
 School Library on N
ovem
ber 3, 2015
http://gastro.oxfordjournals.org/
D
ow
nloaded from
 
